

(51) International Patent Classification:
A61K 31/16 (2006.01)(21) International Application Number:
PCT/US2021/047380(22) International Filing Date:
24 August 2021 (24.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/070,173 25 August 2020 (25.08.2020) US(71) Applicant: **HUYABIO INTERNATIONAL, LLC**
[US/US]; 12531 High Bluff Drive, Suite 138, San Diego,
California 92130 (US).(72) Inventors: **BISSONNETTE, Reid P.**; 12531 High Bluff
Drive, Suite 138, San Diego, California 92130 (US).
CESARIO, Rosemary M.; 12531 High Bluff Drive, Suite
138, San Diego, California 92130 (US). **GOODENOW,**
Robert; 12531 High Bluff Drive, Suite 138, San Diego, Cal-
ifornia 92130 (US). **SHOJAEI, Farbod**; 12531 High Bluff
Drive, Suite 138, San Diego, California 92130 (US). **GIL-****LINGS, Mireille**; 12531 High Bluff Drive, Suite 138, San
Diego, California 92130 (US).(74) Agent: **GUISE, Jeffrey W.**; EVERSHEDS SUTHER-
LAND (US) LLP, 12255 El Camino Real, Suite 100, San
Diego, California 92130 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS




FIG. 1

(57) Abstract: Provided herein is a therapy comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*